1
300
Marquez et al.
1
6. Martinez M, McDermott P, Walker R. Pharmacology of the
fluoroquinolones: a perspective for the use in domestic animals. Vet
J. 2006;172(1):10–28.
REFERENCES
1
. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones
in 2005: an update. Clin Microbiol Infect. 2005;11(4):256–80.
. Michot JM, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM.
Active efflux of ciprofloxacin from J774 macrophages through an
MRP-like transporter. Antimicrob Agents Chemother. 2004;48(7):
17. Cormier R, Burda WN, Harrington L, Edlinger J, Kodigepalli KM,
Thomas J, et al. Studies on the antimicrobial properties of N-acylated
ciprofloxacins. Bioorg Med Chem Lett. 2012;22(20):6513–20.
18. Wang S, Jia XD, Liu ML, Lu Y, Guo HY. Synthesis,
antimycobacterial and antibacterial activity of ciprofloxacin deriva-
tives containing a N-substituted benzyl moiety. Bioorg Med Chem
Lett. 2012;22(18):5971–5.
19. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of
acidic pH on the extracellular and intracellular activities of the anti-
gram-positive fluoroquinolones moxifloxacin and delafloxacin
against Staphylococcus aureus. Antimicrob Agents Chemother.
2011;55(2):649–58.
20. Clinical and Laboratory Standards Institute. Performance standards
for antimicrobial susceptibility testing. 2012;22th informational sup-
plement (MS100-S22).
21. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of
gentamicin, azithromycin, telithromycin, ciprofloxacin,
moxifloxacin, and oritavancin (LY333328) activities against intracel-
lular Staphylococcus aureus in mouse J774 macrophages.
Antimicrob Agents Chemother. 2003;47(7):2283–92.
22. Al Dgither S, Alvi SN, Hammami MM. Development and validation
of an HPLC method for the determination of gatifloxacin stability in
human plasma. J Pharm Biomed Anal. 2006;41(1):251–5.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measure-
ment with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
24. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP,
Tulkens PM. Influence of efflux transporters on the accumulation
and efflux of four quinolones (ciprofloxacin, levofloxacin,
garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob
Agents Chemother. 2005;49(6):2429–37.
2
2
673–82.
3
. Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-
glycoprotein and MRP efflux pump inhibitors on the intracellular
activity of azithromycin and ciprofloxacin in macrophages infected
by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob
Chemother. 2003;51(5):1167–73.
4
5
6
. Marquez B, Van Bambeke F. ABC multidrug transporters: target for
modulation of drug pharmacokinetics and drug-drug interactions.
Curr Drug Targets. 2011;12(5):600–20.
. Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G.
Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci.
2
008;97(9):3483–93.
. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG.
Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquin-
olone antibiotics and affects their oral availability, pharmacokinetics, and
milk secretion. Drug Metab Dispos. 2006;34(4):690–5.
7
. Marquez B, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van
Bambeke F. Identification of the efflux transporter of the fluoroquin-
olone antibiotic ciprofloxacin in murine macrophages: studies with
ciprofloxacin-resistant cells. Antimicrob Agents Chemother.
2
009;53(6):2410–6.
8
9
. Marquez B, Ameye G, Vallet CM, Tulkens PM, Poirel HA, Van
Bambeke F. Characterization of Abcc4 gene amplification in
stepwise-selected mouse J774 macrophages resistant to the topoisom-
erase II inhibitor ciprofloxacin. PLoS One. 2011;6(12):e28368.
. Haslam IS, Wright JA, O’Reilly DA, Sherlock DJ, Coleman T,
Simmons NL. Intestinal ciprofloxacin efflux; the role of breast cancer
resistance protein, BCRP (ABCG2). Drug Metab Dispos.
25. Vassault A. Lactate dehydrogenase. In: Bergemeyer HU, editors.
Methods in enzymatic analysis. VHC Publishers, Veinheim,
Federal Republic of Germany; 1987. p. 118–126.
2
011;39(12):2321–8.
26. Renard C, Vanderhaeghe HJ, Claes PJ, Zenebergh A, Tulkens PM.
Influence of conversion of penicillin G into a basic derivative on its
accumulation and subcellular localization in cultured macrophages.
Antimicrob Agents Chemother. 1987;31(3):410–6.
27. Aubert-Tulkens G, Van Hoof F, Tulkens P. Gentamicin-induced
lysosomal phospholipidosis in cultured rat fibroblasts.
Quantitative ultrastructural and biochemical study. Lab
Invest. 1979;40(4):481–91.
1
1
0. Michot JM, Heremans MF, Caceres NE, Mingeot-Leclercq MP,
Tulkens PM, Van Bambeke F. Cellular accumulation and activity
of quinolones in ciprofloxacin-resistant J774 macrophages.
Antimicrob Agents Chemother. 2006;50(5):1689–95.
1. Lismond A, Tulkens PM, Mingeot-Leclercq MP, Courvalin P, Van
Bambeke F. Cooperation between prokaryotic (Lde) and eukaryotic
(
MRP) efflux transporters in J774 macrophages infected with Listeria
monocytogenes: studies with ciprofloxacin and moxifloxacin.
Antimicrob Agents Chemother. 2008;52(9):3040–6.
2. Vallet CM, Marquez B, Nhiri N, Anantharajah A, Mingeot-Leclercq
MP, Tulkens PM, et al. Modulation of the expression of ABC trans-
porters in murine (J774) macrophages exposed to large concentra-
tions of the fluoroquinolone antibiotic moxifloxacin. Toxicology.
28. Petersen U, Grohe K, Kuehle E, Zeiler H-J, Metzger KG.
Quinolonecarboxylic acids and antibacterial agents containing these
compounds. 17-12-1985;US19840576595 19840203.
29. Montero MT, Freixas J, Hernandez-Borrell J. Expression of the
partition coefficients of a homologous series of 6-fluoroquinolones.
Int J Pharm. 1997;149(2):161–70.
1
2
011;290(2–3):178–86.
30. Kerns EH, Di L. Lipophilicity methods. In: Kerns EH, Di L, editors.
Drug-like properties: concepts, structure design and methods. San
Diego, CA: Academic Press, Elsevier; 2008. p. 260–70.
31. Alovero F, Nieto M, Mazzieri MR, Then R, Manzo RH. Mode of
action of sulfanilyl fluoroquinolones. Antimicrob Agents Chemother.
1998;42(6):1495–8.
1
3. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR.
A convenient assay for estimating the possible involvement of efflux of
fluoroquinolones by Streptococcus pneumoniae and Staphylococcus
aureus: evidence for diminished moxifloxacin, sparfloxacin, and
trovafloxacin efflux. Antimicrob Agents Chemother. 2000;44(3):
7
98–801.
32. Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya
S. Hydrophilicity of quinolones is not an exclusive factor for de-
creased activity in efflux-mediated resistant mutants of
Staphylococcus aureus. Antimicrob Agents Chemother. 1996;40(8):
1835–42.
1
4. Letafat B, Emami S, Mohammadhosseini N, Faramarzi MA, Samadi
N, Shafiee A, et al. Synthesis and antibacterial activity of new N-[2-
(
(
thiophen-3-yl)ethyl] piperazinyl quinolones. Chem Pharm Bull
Tokyo). 2007;55(6):894–8.
1
5. Pieroni M, Dimovska M, Brincat JP, Sabatini S, Carosati E, Massari
S, et al. From 6-aminoquinolone antibacterials to 6-amino-7-
thiopyranopyridinylquinolone ethyl esters as inhibitors of
Staphylococcus aureus multidrug efflux pumps. J Med Chem.
33. Piddock LJ, Jin YF, Griggs DJ. Effect of hydrophobicity and molecular
mass on the accumulation of fluoroquinolones by Staphylococcus aureus.
J Antimicrob Chemother. 2001;47(3):261–70.
34. Godreuil S, Galimand M, Gerbaud G, Jacquet C, Courvalin P.
Efflux pump Lde is associated with fluoroquinolone resistance in
2
010;53(11):4466–80.